Association between Serum Levels of Interleukin-6 and Stage of Laryngeal Cancer

Document Type: Original

Authors

1 Hearing & Speech Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Hearing & Speech research center of Ahvaz Jundishapur university of medical sciences

Abstract

Introduction:
The purpose of this study was to investigate the relationship between serum levels of interleukin-6 (IL-6) and the severity and extent of squamous cell carcinoma (SCC) of the larynx based on stage of tumor progression and histological grade.
 
Materials and Methods:
All patients with a diagnosis of laryngeal cancer who underwent laryngoscopy and biopsy while hospitalized in Imam Khomeini Hospital in Ahvaz were enrolled. Tumor stage was calculated based on the TNM system, and divided into early (stage 1,2) or advanced stage (stage 3,4). In addition, patients were divided into low-grade (well differentiated) or high-grade (moderate and poorly differentiated) groups based on pathology reports from biopsy specimens. Several healthy volunteers were also enrolled as the control group. After collecting the blood samples, quantitative serum levels of IL-6 were measured (pmol/L) using IL-6 kits (Bender MedSystem, Germany). Results for quantitative variables are presented as mean and standard deviation and qualitative variables as percentages. Mann-Whitney, Kruskal-Wallis and Pearson’s chi square tests were used for statistical analyses.
Results:
Thirty-eight patients (82.6%) were male and eight patients (17.4%) were female. IL-6 serum level was 28.8±4.7 pmol/L in the patient group and 2.64±2.88 pmol/L in the control group (P=0.0001). The serum level of IL-6 was 7.27 ± 5.31 pmol/L in early-stage patients and 54.43 ± 6.06 pmol/L in advanced-stage patients (P<0.0001). IL-6 levels increased significantly with increasing N (according to TNM) (P=0.002). Levels of IL-6 in patients with metastasis were significantly higher than in the group without metastasis (P=0.024). Moreover, IL-6 levels increased significantly with increasing local tumor spread (T) (P<0.0001).
 
Conclusion: 
This study shows that IL-6 is a gender-independent factor, serum levels of which are higher in patients with laryngeal SCC than in normal subjects. The results of this study also show that serum levels of this cytokine increase significantly with progression of this malignancy.

Keywords

Main Subjects


1. Armstrong WB, Vokes D, Maisel RH. Malignant tumor of the larynx. In: Cummings CW, Flint PW, Harker LA, Haughey BH, Richardson MA, Robbins KT, et al.(editors).Cummings Otolaryngology Head & Neck Surgery. 5th ed. Philadelphia: Elsevier Mosby; 2010:1482–1510.

2. Lopez RVM, Zago MA, Eluf-Neto J. Education, tobacco smoking, alcohol consumption, and IL-2 and IL-6gene polymorphisms in the survival of head and neck cancer. Medical and Biological Res 2011; 44(10):1006–12.

3. Duffy S, Taylor J, Terrel J. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. American Cancer Society 2008(4): 750–7.

4. Mojtahedi Z, Khademi B, Hashemi SB. Serum interleukin-6 concentration but not Interleukin-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res 2011; 17(1): 7–10.

5. Blay JY, Negrier S, Combaret V. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res1992; 52:3317–22.

6. Scambia G, Testa U, Benedetti Panici P. Prognostic significance of interleukin 6 serum level in patient with ovarian cancer. Br J Cancer 1995; 71(2):354–6.

7. O’Regan EM, Timon C, Sheils O, Codd M, Oleary JJ, Toner M. Squamous cell carcinoma of the head and neck in young Irish adults. Br J Oral Maxillofac Surg 2006; 44(3): 203–6.

8. Mafi N, Kadivar M, Hosseini N, Ahmadi S, Zare Mirzaie A, et al. Head and neck squamous cell carcinoma in Iranian patients and risk factors in young adults: a fifteen-year study. Asian Pac J Cancer Prev 2012; 13: 3373–8.

9. Saki N, Saki G, Maasomi SA, Rahim F, Emad Mostofi N, Nikakhlagh S. Effect of smoking in the etiology of cancer of larynx in Khuzestan. Jentashpir Journal 2011; 2(3):99–103.

10. Saedi B, Razmpa E, Sadeghi M, Mojtahed M, Mojtahed A, et al. The epidemiology of laryngeal cancer in a country on the esophageal cancer belt. Indian J Otolaryngol Head Neck Surg 2009;      61:213-17.

11. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance.  Nat Rev Cancer 2005; 5: 263–74.

12. Kinoshita T, Ito H and Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85(12):2526–31.          

13. Oka M, Iizuka N, Yamamoto K, Gondo T, Abe T, Hazama S, Akitomi Y, Koishihara Y, Ohsugi Y, Ooba Y, Ishihara T, et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16(12): 1001–6.

14. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83–5.

15. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as
an in vitroautocrine growth factor in renal cell carcinomas. FEBS Lett 1989(2); 250: 607–10.

16. Meir EV, Sawamura Y, Diserens A, Hamou M, Tribolet N. Human glioblastoma cells release interleukin-6 in vivo and in vitro. Cancer Res 1990; 50: 6683–8.

17. Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, et al. Growth inhibition of human lung cancer cell lines by interleukin-6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 1993; 53:   4175–81.

18. Teague TK, Marrack P, John WK, Anthony TV. IL-6 rescues resting mouse T cell from apoptosis. J Immunol 1997; 158(12): 5791–96.

19. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84(6): 2008–11.

20. Tsukamoto T, Kumanoto Y, Miyao N, Masumori N, Takahashi A, Yanase M. Interleukin-6 in renal cell carcinoma. J Urol 1982; 148(6); 1778–82.

21. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 1996; 56: 27–2780.

22. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, Peng FK, et al. Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroentrol 1996; 91(7):1417–22.

23. Jacobs C. The internist in the management of head and neck cancer. Ann Intern Med 1990; 113(10):771–8.

24. Hao W, Zhu Y, Zhou H. Prognostic value of interleukin-6 and interleukin-8 in laryngeal squamous cell cancer. Med Oncol 2013;30(1):333.

25. Riedel F, Zaiss I, Herzog D, Götte K, Naim R, Hörmann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005; 25(4):2761–5.

26. Bolkheir A, Khademi B, Habib Agahi M, Ghaderi A, Hosseini A, Jaberipour M. FOXP3, CTLA-4 & IL-10 genes expression in patients with laryngeal cancer and corresponding metastases. ISMJ 2013; 16(3):167–80.